We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-6.35%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.4B
AUM Growth
-$782M
Cap. Flow
+$157M
Cap. Flow %
1.38%
Top 10 Hldgs %
87.68%
Holding
124
New
6
Increased
21
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$234M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$100M
3
ASND icon
Ascendis Pharma A/S
ASND
+$10.6M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.37M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$6.88M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$69.3M
2
DERM
Dermira, Inc.
DERM
+$14.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.5M
4
EXEL icon
Exelixis
EXEL
+$11M
5
CERS icon
Cerus
CERS
+$9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.03%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
26
DELISTED
Immunogen Inc
IMGN
$21.4M 0.19%
3,015,353
– –
PGNX
27
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$21.4M 0.19%
3,150,808
– –
HALO icon
28
Halozyme
HALO
$12.3B
$20.3M 0.18%
1,581,424
+189,917
+14% +$2.54M
LKFT
29
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$19.9M 0.17%
259,894
– –
XNCR icon
30
Xencor
XNCR
$2.07B
$18.4M 0.16%
872,072
– –
MRUS
31
DELISTED
Merus
MRUS
$18.4M 0.16%
1,160,014
– –
ACGN
32
DELISTED
Aceragen Inc
ACGN
$17.7M 0.15%
75,774
+62
+0.1% +$16.2K
NDRM
33
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$17.1M 0.15%
571,667
– –
NTLA icon
34
Intellia Therapeutics
NTLA
$1.8B
$17M 0.15%
1,062,120
– –
SAGE
35
DELISTED
Sage Therapeutics
SAGE
$16.6M 0.15%
208,328
– –
AERI
36
DELISTED
Aerie Pharmaceuticals
AERI
$15.7M 0.14%
299,356
– –
LJPC
37
DELISTED
La Jolla Pharmaceutical Company
LJPC
$15M 0.13%
504,732
+125,598
+33% +$3.6M
CPRX
38
DELISTED
Catalyst Pharmaceutical
CPRX
$14.1M 0.12%
5,102,153
– –
AIMT
39
DELISTED
Aimmune Therapeutics
AIMT
$13.9M 0.12%
673,908
– –
ARRY
40
DELISTED
Array Biopharma Inc
ARRY
$13.3M 0.12%
1,585,913
– –
FOMX
41
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$11.4M 0.1%
2,466,702
– –
LOXO
42
DELISTED
Loxo Oncology, Inc
LOXO
$11.1M 0.1%
138,312
+577
+0.4% +$32K
ABEO icon
43
Abeona Therapeutics
ABEO
$348M
$10.8M 0.09%
67,375
– –
RXDX
44
DELISTED
Ignyta, Inc.
RXDX
$9.27M 0.08%
896,000
+325,000
+57% +$2.64M
SYRS
45
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.25M 0.08%
57,484
+37,037
+181% +$5.82M
LGND icon
46
Ligand Pharmaceuticals
LGND
$5.71B
$8.91M 0.08%
117,638
– –
ALKS icon
47
Alkermes
ALKS
$8.11B
$8.71M 0.08%
150,251
– –
ACHN
48
DELISTED
Achillion Pharmaceuticals
ACHN
$8.52M 0.07%
1,856,637
– –
MRTX
49
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.28M 0.07%
2,269,198
– –
ITCI
50
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.57M 0.07%
609,166
– –
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2017 Portfolio in Review

As of Q2 2017, Julian Baker held 124 positions worth $11.4B, down 6.4% from $12.2B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Julian Baker's Q2 2017 filing shows 6 new, 21 increased, 9 reduced and 4 closed positions. Its largest new stake was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M. The largest sale was Acorda Therapeutics, an estimated $69.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q2 2017 buy was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M.
  • Julian Baker added most to Alexion Pharmaceuticals in Q2 2017, an estimated $234M increase.
  • Julian Baker's biggest Q2 2017 reduction was Neurocrine Biosciences, cutting an estimated $13.5M.
  • Julian Baker fully exited Acorda Therapeutics in Q2 2017, selling an estimated $69.3M.
  • Julian Baker's ten largest holdings make up 88% of its $11.4B portfolio in Q2 2017.
  • Julian Baker opened 6 new positions and closed 4 in Q2 2017.
  • Julian Baker's portfolio value fell 6.4% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.